Selective use of daunorubicin for remission‐induction chemotherapy in acute non‐lymphoblastic leukemia

B. S. Shaikh, J. B. Dougherty, Robert Hamilton, James Ballard, S. B. Patel, N. R. Gevirtz, M. Elaine Eyster

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Twenty‐eight patients with acute non‐lymphoblastic leukemia (ANLL) were started on induction chemotherapy consisting of Cytosine Arbinoside (Ara C) and 6 thioguanine (TG). Daunorubicin (DNR) was used selectively in 20 of 28 patients who failed to respond by day 14 to the Ara C and TG combination. Seven patients, or 25%, achieved complete remission (CR) without requiring DNR during remission induction. The overall response rate was 89% (64% CR and 25% PR). The median duration of survival for the CR group was 578 days. 189 days for the partial remission (PR) group (P = .02). Patients in the age group of 18–40 years and with acute myelomonocytic leukemia subtype had the best response rate. There was no difference in the survival of the DNR treated group of complete responders as compared to DNR non‐treated group. These results suggest that even though the majority of patients do require DNR for the remission induction, a significant number, perhaps as high as 25% of previously untreated patients, will achieve remission without the use of DNR. A significant minority of patients can, therefore, be spared the toxicity of DNR early in the course of their disease.

Original languageEnglish (US)
Pages (from-to)1731-1734
Number of pages4
JournalCancer
Volume46
Issue number8
DOIs
StatePublished - Jan 1 1980

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Selective use of daunorubicin for remission‐induction chemotherapy in acute non‐lymphoblastic leukemia'. Together they form a unique fingerprint.

  • Cite this